5.9 USD
-0.07 (-1.17%)
5.65 USD
-0.25 (-4.24%)
Overall ICCC gets a fundamental rating of 4 out of 10. We evaluated ICCC against 530 industry peers in the Biotechnology industry. ICCC has an average financial health and profitability rating. ICCC has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ICCC was profitable.
In the past year ICCC had a positive cash flow from operations.
ICCC had negative earnings in each of the past 5 years.
In multiple years ICCC reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.08%, ICCC belongs to the top of the industry, outperforming 91.32% of the companies in the same industry.
The Return On Equity of ICCC (7.80%) is better than 91.70% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.41%, ICCC belongs to the top of the industry, outperforming 90.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROIC | 4.41% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 8.37%, ICCC belongs to the top of the industry, outperforming 90.38% of the companies in the same industry.
Looking at the Operating Margin, with a value of 8.39%, ICCC belongs to the top of the industry, outperforming 90.75% of the companies in the same industry.
Looking at the Gross Margin, with a value of 40.93%, ICCC is in the better half of the industry, outperforming 73.96% of the companies in the same industry.
ICCC's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICCC is destroying value.
Compared to 1 year ago, ICCC has more shares outstanding
ICCC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ICCC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.74 indicates that ICCC is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICCC has a Altman-Z score of 2.74. This is in the better half of the industry: ICCC outperforms 67.74% of its industry peers.
The Debt to FCF ratio of ICCC is 13.27, which is on the high side as it means it would take ICCC, 13.27 years of fcf income to pay off all of its debts.
ICCC has a Debt to FCF ratio of 13.27. This is amongst the best in the industry. ICCC outperforms 90.00% of its industry peers.
ICCC has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
ICCC has a worse Debt to Equity ratio (0.27) than 69.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Altman-Z | 2.74 |
ROIC/WACC0.53
WACC8.34%
2.3 Liquidity
A Current Ratio of 4.21 indicates that ICCC has no problem at all paying its short term obligations.
ICCC's Current ratio of 4.21 is in line compared to the rest of the industry. ICCC outperforms 50.57% of its industry peers.
ICCC has a Quick Ratio of 1.76. This is a normal value and indicates that ICCC is financially healthy and should not expect problems in meeting its short term obligations.
ICCC has a Quick ratio of 1.76. This is in the lower half of the industry: ICCC underperforms 78.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 152.00% over the past year.
The Revenue has grown by 16.49% in the past year. This is quite good.
ICCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.07% yearly.
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.69, ICCC is valued on the expensive side.
Based on the Price/Earnings ratio, ICCC is valued cheaply inside the industry as 93.96% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ICCC to the average of the S&P500 Index (26.61), we can say ICCC is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.69 | ||
| Fwd PE | N/A |
4.2 Price Multiples
ICCC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICCC is cheaper than 96.23% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ICCC is valued cheaply inside the industry as 92.08% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 74.64 | ||
| EV/EBITDA | 11.74 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ICCC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.9
-0.07 (-1.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.56%
Inst Owner Change-3.09%
Ins Owners26.35%
Ins Owner Change0.51%
Market Cap53.40M
Revenue(TTM)27.77M
Net Income(TTM)2.32M
Analysts82.86
Price TargetN/A
Short Float %0.1%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.69 | ||
| Fwd PE | N/A | ||
| P/S | 1.92 | ||
| P/FCF | 74.64 | ||
| P/OCF | 26.84 | ||
| P/B | 1.79 | ||
| P/tB | 1.8 | ||
| EV/EBITDA | 11.74 |
EPS(TTM)0.26
EY4.41%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.34%
OCF(TTM)0.22
OCFY3.73%
SpS3.07
BVpS3.29
TBVpS3.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROCE | 5.58% | ||
| ROIC | 4.41% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 4.87% | ||
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% | ||
| FCFM | 2.58% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Debt/EBITDA | 1.57 | ||
| Cap/Depr | 47.25% | ||
| Cap/Sales | 4.59% | ||
| Interest Coverage | 5.01 | ||
| Cash Conversion | 39.59% | ||
| Profit Quality | 30.79% | ||
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 2.74 |
F-Score7
WACC8.34%
ROIC/WACC0.53
Cap/Depr(3y)82.27%
Cap/Depr(5y)105.22%
Cap/Sales(3y)11.34%
Cap/Sales(5y)14.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.97%
OCF growth 3Y-27.78%
OCF growth 5Y9.25%
IMMUCELL CORP / ICCC FAQ
Can you provide the ChartMill fundamental rating for IMMUCELL CORP?
ChartMill assigns a fundamental rating of 4 / 10 to ICCC.
Can you provide the valuation status for IMMUCELL CORP?
ChartMill assigns a valuation rating of 4 / 10 to IMMUCELL CORP (ICCC). This can be considered as Fairly Valued.
Can you provide the profitability details for IMMUCELL CORP?
IMMUCELL CORP (ICCC) has a profitability rating of 5 / 10.
What is the valuation of IMMUCELL CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IMMUCELL CORP (ICCC) is 22.69 and the Price/Book (PB) ratio is 1.79.
Can you provide the financial health for ICCC stock?
The financial health rating of IMMUCELL CORP (ICCC) is 5 / 10.